Altasciences Acquires Sinclair Research

Altasciences Acquires Alliance Contract Pharma

February 27, 2020

Pharmaceuticals

Altasciences, a mid-size contract research organization based in Laval, Quebec, has acquired Alliance Contract Pharma to add small-molecule contract manufacturing and analytical services, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution. The acquisition expands Altasciences' integrated early‑phase drug development offering by adding manufacturing and analytical capabilities to its preclinical, clinical, and bioanalytical services.

Novo Holdings Acquires Altasciences from Audax Private Equity

February 22, 2021

Healthcare Services

Novo Holdings has agreed to acquire Altasciences, a Laval, Canada–headquartered contract research and CDMO services provider, from Audax Private Equity. Altasciences— which operates six facilities across the U.S. and Canada and employs over 1,300 people—will remain led by CEO Chris Perkin and is expected to continue expanding domestically and internationally under Novo Holdings' ownership.

Altasciences Acquires WCCT Global

February 12, 2021

Healthcare Services

Altasciences acquired WCCT Global, an early‑stage clinical research organization (CRO) based in Southern California, expanding its West Coast clinical pharmacology capabilities and adding 180 clinical beds. The transaction, completed February 12, 2021, augments Altasciences’ Phase I/II services and expertise in specialized areas such as ethnobridging to support biopharmaceutical sponsors.

ACL Digital Acquires Symbiance

September 26, 2025

Healthcare Services

ACL Digital, an ALTEN Group company, has acquired Symbiance, a US-based contract research organization (CRO) that provides clinical data management, biostatistics, medical writing and pharmacovigilance services. The acquisition expands ACL Digital's life sciences capabilities by adding AI-driven clinical research, CRO and pharmacovigilance expertise to its digital transformation and engineering services.

Sygnature Discovery Acquires NuChem Sciences

August 1, 2023

Biotechnology

UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.